autoimmune diseases

News

Hutchmed scores with drug for rare autoimmune disease

Hutchmed is preparing to file for approval of its drug for the rare disorder wAIHA in China, after chalking up a win in a pivotal phase 2/3 trial.

R&D

pharmaphorum podcast Episode 239, Dr Jorg Schuttrumpf

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

News

Kyverna rises on stiff person syndrome data

Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.

News

J&J gets EU approval for Imaavy in gMG

J&J's Imaavy has become the first FcRn blocker to be approved in the EU for both adolescent and adult patients with generalised myasthenia gravis.

News

BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics, a developer of in vivo cell therapies, for $1.5bn in cash.

News

Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi

Regulatory T-cell scientist trio wins Nobel Prize

The Nobel Prize in Physiology or Medicine goes to three scientists for their work on regulatory T-cells, spawning hundreds of trials of new therapies.

Hutchmed scores with drug for rare autoimmune disease

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Kyverna rises on stiff person syndrome data

J&J gets EU approval for Imaavy in gMG

BMS builds in 'in vivo' cell therapy with $1.5bn Orbital buy

Regulatory T-cell scientist trio wins Nobel Prize

Madrigal eyes combination MASH therapy with Pfizer deal

How to meet your physicians where they are online

autoimmune diseases

Editor's Picks